Mosher-Clark v. Gravity Defyer Medical Technology Corporation

CourtDistrict Court, N.D. California
DecidedSeptember 8, 2023
Docket4:22-cv-05288
StatusUnknown

This text of Mosher-Clark v. Gravity Defyer Medical Technology Corporation (Mosher-Clark v. Gravity Defyer Medical Technology Corporation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mosher-Clark v. Gravity Defyer Medical Technology Corporation, (N.D. Cal. 2023).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 CECELIA MOSHER-CLARK, Case No. 22-cv-05288-HSG

8 Plaintiff, ORDER GRANTING IN PART AND DENYING IN PART DEFENDANT'S 9 v. MOTION TO DISMISS

10 GRAVITY DEFYER MEDICAL Re: Dkt. No. 31 TECHNOLOGY CORPORATION, 11 Defendant. 12 13 This putative class action lawsuit alleges that Defendant Gravity Defyer Medical 14 Technology Corporation (“Defendant” or “Gravity Defyer”) deceives consumers into purchasing 15 shoes that do not provide the advertised clinically proven pain relief. Dkt. No. 30 (“FAC”). 16 Before the Court is Defendant’s motion to dismiss, which is fully briefed. Dkt. Nos. 31 (“Mot.”), 17 32 (“Opp.”), 33 (“Reply”). The Court finds this matter appropriate for disposition without oral 18 argument, see Civil 7-1(b), and GRANTS IN PART and DENIES IN PART the motion. 19 I. BACKGROUND 20 The following allegations are drawn from the FAC. Defendant is a designer and 21 manufacturer of shoes worn to relieve knee, ankle, foot, and back pain using “VersoShock” 22 technology. FAC ¶¶ 1,7. Defendant commissioned a study by the Olive View-UCLA Medical 23 Center (the “UCLA Study”) to conduct a clinical evaluation of its shoes. FAC ¶¶ 2, 11, n.4. The 24 UCLA Study was a double-blind study which Defendant used to advertise that its shoes were 25 “clinically shown to relieve knee pain” by 85%, along with back pain by 91%, ankle pain by 92%, 26 and foot pain by 75%. FAC ¶ 11. Based on advertisements citing the UCLA study, the FTC sued 27 Defendant in May 2022, alleging “misrepresentations through user testimonials or about tests, 1 Corp., No. 1:22-cv-01464 (D.D.C. May 25, 2022)).1 2 In April 2021, Cecelia Mosher-Clarke (“Plaintiff”) purchased a pair of Mighty Walk shoes, 3 designed and manufactured by Defendant with VersoShock technology, on Amazon.com for $135. 4 FAC ¶ 24. In making her purchase, Plaintiff alleges she relied on Defendant’s website advertising 5 materials and Amazon’s product page. FAC ¶¶ 11-12, 24. After wearing the shoes “four days a 6 week for fourteen hours per day” for two months, Plaintiff alleges she did not experience any pain 7 relief. FAC ¶ 24. The FAC cuts and pastes twenty-one negative Amazon reviews of the Ion shoe 8 model, which is also manufactured by Defendant and contains VersoShock technology. FAC n. 1, 9 ¶ 16. 10 In August 2022, Plaintiff served a demand letter on Defendant, then filed suit in September 11 2022. FAC ¶ 111. Plaintiff’s complaint, amended in February 2023, disavows relying on the 12 theory that the UCLA Study does not substantiate Defendant’s advertisements, but instead 13 contends that Defendant’s representations are false because “Defendant’s Footwear cannot, and 14 does not, provide pain relief.” FAC ¶¶ 15, 20. 15 II. LEGAL STANDARD 16 Federal Rule of Civil Procedure 8(a) requires that a complaint contain “a short and plain 17 statement of the claim showing that the pleader is entitled to relief.” Fed. R. Civ. P. 8(a)(2). A 18 defendant may move to dismiss a complaint for failing to state a claim upon which relief can be 19 granted under Rule 12(b)(6). “Dismissal under Rule 12(b)(6) is appropriate only where the 20 complaint lacks a cognizable legal theory or sufficient facts to support a cognizable legal theory.” 21 Mendiondo v. Centinela Hosp. Med. Ctr., 521 F.3d 1097, 1104 (9th Cir. 2008). To survive a Rule 22 12(b)(6) motion, a plaintiff need only plead “enough facts to state a claim to relief that is plausible 23 on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible 24 when a plaintiff pleads “factual content that allows the court to draw the reasonable inference that 25 the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). 26 Rule 9(b) imposes a heightened pleading standard where fraud is an essential element of a 27 1 claim. See Fed. R. Civ. P. 9(b) (“In alleging fraud or mistake, a party must state with particularity 2 the circumstances constituting fraud or mistake.”); see also Vess v. Ciba–Geigy Corp. USA, 317 3 F.3d 1097, 1107 (9th Cir. 2003). A plaintiff must identify “the who, what, when, where, and how” 4 of the alleged conduct, so as to provide defendants with sufficient information to defend against 5 the charge. Cooper v. Pickett, 137 F.3d 616, 627 (9th Cir. 1997). However, “[m]alice, intent, 6 knowledge, and other conditions of a person's mind may be alleged generally.” Fed. R. Civ. P. 7 Rule 9(b). 8 In reviewing the plausibility of a complaint, courts “accept factual allegations in the 9 complaint as true and construe the pleadings in the light most favorable to the nonmoving party.” 10 Manzarek v. St. Paul Fire & Marine Ins. Co., 519 F.3d 1025, 1031 (9th Cir. 2008). Nevertheless, 11 courts do not “accept as true allegations that are merely conclusory, unwarranted deductions of 12 fact, or unreasonable inferences.” In re Gilead Scis. Secs. Litig., 536 F.3d 1049, 1055 (9th Cir. 13 2008) (quoting Sprewell v. Golden State Warriors, 266 F.3d 979, 988 (9th Cir. 2001)). And even 14 where facts are accepted as true, “a plaintiff may plead [him]self out of court” if he “plead[s] facts 15 which establish that he cannot prevail on his ... claim.” Weisbuch v. Cty. of Los Angeles, 119 F.3d 16 778, 783 n.1 (9th Cir. 1997) (quotation omitted). 17 Even if the court concludes that a 12(b)(6) motion should be granted, the “court should 18 grant leave to amend even if no request to amend the pleading was made, unless it determines that 19 the pleading could not possibly be cured by the allegation of other facts.” Lopez v. Smith, 203 20 F.3d 1122, 1127 (9th Cir. 2000) (en banc) (quotation omitted). 21 III. DISCUSSION 22 A. UCL, CLRA, FAL Claims 23 Plaintiff’s claims under California's Unfair Competition Law (UCL), False Advertising 24 Law (FAL), and Consumer Legal Remedies Act (CLRA) are based on the theory that Defendant’s 25 representation that its shoes are clinically proven to provide pain relief is false because the shoes 26 do not in fact provide such relief. FAC ¶¶ 5, 42, 43, 72. The UCL prohibits any “unlawful, unfair 27 or fraudulent business act or practice and unfair, deceptive, untrue or misleading advertising.” 1 plaintiff must plausibly allege that the defendant's product claims are false or misleading. 2 Williams v. Gerber Prods., Co., 552 F.3d 934, 938 (9th Cir. 2008). A plaintiff may establish 3 falsity “by testing, scientific literature, or anecdotal evidence.” Nat'l Council Against Health 4 Fraud Inc. v. King Bio Pharms. Inc., 107 Cal. App. 4th 1336, 1345-46 (2003). The “unlawful” 5 prong of the UCL incorporates other laws and treats violations of those laws as unlawful business 6 practices independently actionable under state law. Chabner v. United Omaha Life Ins. Co., 225 7 F.3d 1042, 1048 (9th Cir. 2000).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
John Meyers v. City of Cincinnati
14 F.3d 1115 (Sixth Circuit, 1994)
Manzarek v. St. Paul Fire & Marine Insurance
519 F.3d 1025 (Ninth Circuit, 2008)
Burr v. Sherwin Williams Co.
268 P.2d 1041 (California Supreme Court, 1954)
Williams v. Gerber Products Co.
552 F.3d 934 (Ninth Circuit, 2008)
Mendiondo v. Centinela Hospital Medical Center
521 F.3d 1097 (Ninth Circuit, 2008)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Williams v. Beechnut Nutrition Corp.
185 Cal. App. 3d 135 (California Court of Appeal, 1986)
National Council Against Health Fraud, Inc. v. King Bio Pharmaceuticals, Inc.
133 Cal. Rptr. 2d 207 (California Court of Appeal, 2003)
Lavie v. Procter & Gamble Co.
129 Cal. Rptr. 2d 486 (California Court of Appeal, 2003)
Isip v. Mercedes-Benz USA, LLC
65 Cal. Rptr. 3d 695 (California Court of Appeal, 2007)
Tamara Moore v. Mars Petcare US, Inc.
966 F.3d 1007 (Ninth Circuit, 2020)
Heather Floyd v. American Honda Motor Co., Inc.
966 F.3d 1027 (Ninth Circuit, 2020)
McKell v. Washington Mutual, Inc.
142 Cal. App. 4th 1457 (California Court of Appeal, 2006)
Nicholas Shoner v. Carrier Corporation
30 F.4th 1144 (Ninth Circuit, 2022)
Jones v. Resolution Trust Corp.
7 F.3d 1006 (Eleventh Circuit, 1993)
Cooper v. Pickett
137 F.3d 616 (Ninth Circuit, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Mosher-Clark v. Gravity Defyer Medical Technology Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mosher-clark-v-gravity-defyer-medical-technology-corporation-cand-2023.